| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2026-007 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于全资孙公司向公司控股股东借款展期暨关联交 易进展的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为了满足日常运营需要，美国孙公司向公司控股股东、实际控制人徐久振 先生借款，借款额度不超过美元 60 万元，借款期限自 2023 年 2 月 20 日起不 超过 1 年，借款年利率综合参考人民币及美元的银行同期贷款基准利率，不超 过其中较低者。美国孙公司可以根据实际情况在借款期限及额度内连续循环使 用。公司及美国孙公司就本次借款无需提供保证、抵押、质押等任何形式的担 保。2023 年 2 月 20 日，上述事项已经公司第四届董事会第六次会议及第四届 监事会第三次会议审议通过，具体内容详见公司于 2023 年 2 月 22 日在上海证 券交易所网站(www.sse.com.cn)披露的《上海阿拉丁生化科技股 ...

一、董事会会议召开情况 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2026-010 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 第五届董事会第二次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2026 年 2 月 6 日以现场会议结合通讯方式召开了公司第五届董事会第二次会议（以下简称"本 次会议"）。本次会议的通知于 2026 年 2 月 2 日通过书面方式送达全体董事。会 议应出席董事 7 人，实际到会董事 7 人，会议由公司董事长徐久振先生主持，公 司其他相关人员列席会议。本次会议的召集、召开程序符合国家有关法律、法规 和《公司章程》、《董事会议事规则》的规定。本次会议的召开程序、表决结果均 合法有效。 二、董事会会议审议情况 本次会议由公司董事长徐久振先生主持，经全体董事表决，形成决议如下： (一) 审议通过《关于全资孙公司向公司控股股东 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2026-008 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于调整公司 2021 年限制性股票激励计划 相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票授予价格由 11.58 元/股调整为 11.51 元/股 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）于 2026 年 2 月 6 日召开第五届董事会第二次会议审议通过了《关于调整公司 2021 年限制性股票激励计划相关事项的议案》，同意根据《上市公司股权激励管理办 法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）、公司《2021 年限制性股票激励计划（草案）》 （以下简称"《激励计划》"、"本激励计划"）的有关规定，以及公司 2021 年第二次临时股东大会的授权，公司董事会对 2021 年限制性股票激励计 ...

地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 调整 2021 年限制性股票激励计划相关事项的 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 调整 2021 年限制性股票激励计划相关事项的 法律意见书 致：上海阿拉丁生化科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海阿拉丁生化科技股份有限公司 （以下简称"公司"或"阿拉丁"）的委托，并根据公司与本所签订的法律服务合同，作为公 司 2021 年限制性股票激励计划（以下简称"本次激励计划"）的法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称"《 ...

Core Viewpoint - The announcement details the appointment of Ms. Zhao Yahui as the Secretary of the Board of Shanghai Aladdin Biochemical Technology Co., Ltd., following her completion of the required training and qualification process [1][2]. Group 1: Appointment Details - The Board of Directors approved the appointment of Ms. Zhao Yahui as the Secretary of the Board during the first meeting of the fifth Board on December 26, 2025 [1]. - Ms. Zhao's term will be effective upon obtaining the necessary training certification and will last until the end of the fifth Board's term [1]. - The company has submitted Ms. Zhao's qualifications for the Secretary position to the Shanghai Stock Exchange, which has been approved without objections [2]. Group 2: Training and Responsibilities - Ms. Zhao completed the training for the Secretary of the Board at the Shanghai Stock Exchange and passed the examination, obtaining the necessary certification [2]. - Following the approval of her qualifications, Ms. Zhao officially assumes her responsibilities as the Secretary of the Board, relieving the current Chairman, Mr. Xu Jiuzhen, from acting in this role [2]. Group 3: Contact Information - The contact details for the Secretary of the Board are provided, including a phone number, email address, and physical address in Shanghai [3].

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2026-006 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于董事会秘书取得任职培训证明并正式履职的公告 上海阿拉丁生化科技股份有限公司 董事会 2026 年 2 月 3 日 公司董事会秘书联系方式如下： 联系电话：021-50560989 邮箱：aladdindmb@163.com 联系地址：上海市浦东新区新金桥路 36 号南塔 16 层 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日 召开了第五届董事会第一次会议，审议通过了《关于聘任赵亚红女士为公司第五届 董事会秘书的议案》，董事会同意聘任赵亚红女士担任公司董事会秘书，任期自其 取得任职培训相关证明后正式生效，至第五届董事会届满之日止。具体内容详见公 司于 2025 年 12 月 27 日在上海证券交易所网站（w ...

Summary of Aladdin Company Conference Call Industry and Company Overview - Aladdin Company is focused on the semiconductor industry, implementing a domestic substitution strategy to increase revenue from tens of millions to over a billion in profit [2][4] - The company has achieved significant profit through acquisitions, although some acquisitions are not fully controlled, resulting in profits of over 100 million [2][4] Key Points and Arguments Domestic Market Performance - Monthly production of the company's debonding agent is currently 20 tons, with plans to expand to 50 tons by May, but demand still exceeds supply [2][3][7] - The price of the debonding agent is approximately 100,000 RMB per ton, significantly lower than the foreign price of 1,000,000 RMB per ton, addressing critical supply chain issues [2][7] Product Development and Customer Relationships - Aladdin has established strong partnerships with major domestic semiconductor clients by providing debonding agents and cleaning solutions, and is actively developing complementary products like etching solutions [2][6] - The etching solution has been validated by customers and is ready for mass production, with an expected annual demand of hundreds of tons [3][10] Financial Projections and Goals - The company aims for overseas revenue of $500-600 million in 2026, with costs exceeding $100 million, and expects to achieve profitability with a net profit margin potentially exceeding 50% [2][5] - Future revenue targets include $30 million in two to three years, with net profits reaching $50-60 million, effectively doubling the company's size [5][13] Strategic Directions - Aladdin's future strategy includes strengthening its core business, expanding into overseas markets, and seeking complementary investment opportunities [2][8] - The company plans to enhance market share through domestic substitution and improve gross margins in overseas markets [8] Pricing and Profitability Strategy - Initial product pricing was low, but as experience and demand grow, prices are expected to increase, with current gross margins nearing 90% [9] - The company is negotiating price increases with clients, which could further enhance profitability despite significant R&D investments [9] Technical Advantages - Aladdin's competitive edge lies in its technical capabilities, rapid response from R&D, and strong purification and quality control abilities [12] - The ability to adjust formulations to meet specific customer needs has helped establish long-term partnerships [12] Overseas Business Development - Aladdin began preparations for international expansion in 2018, establishing a warehouse in the U.S. in 2023 and expecting overseas sales to grow significantly [13] - The company has also invested in a large warehouse in Frankfurt and has a stake in an e-commerce platform to support future sales growth [13] Management Support for Projects - An independent team has been established to manage new projects, led by the chairman, with approximately 15-16 members dedicated to supporting development and implementation [14]

Market Performance - The recombinant protein sector declined by 0.62%, ranking among the top losers in the concept sectors, with *ST WanFang hitting the daily limit down [1] - Notable declines in the sector included Aladdin, Zexing Pharmaceutical, and Shutaishen, while 18 stocks within the sector saw price increases, with Haitai Biological, Yabao Pharmaceutical, and Zhongyuan Qihe leading with gains of 4.28%, 1.17%, and 1.08% respectively [1] Capital Flow - The recombinant protein sector experienced a net outflow of 479 million yuan, with 41 stocks seeing net outflows, and 6 stocks with outflows exceeding 30 million yuan [1] - The stock with the highest net outflow was Xilong Science, with a net outflow of 59.20 million yuan, followed by Aladdin, Shutaishen, and Aimeike with outflows of 50.46 million yuan, 39.78 million yuan, and 39.10 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included Haitai Biological, with a gain of 4.28%, and the top losers included Aladdin and Shutaishen, with declines of 6.46% and 2.49% respectively [1][2] - Other notable stocks with significant capital inflows included Haitai Biological, Huayu Pharmaceutical, and Tonghua Dongbao, with net inflows of 17.77 million yuan, 15.97 million yuan, and 9.97 million yuan respectively [3]

Group 1 - The A-share market continues to show strength in the chemical sector, with notable stock increases including Hongbaoli up 9%, Jujiao Co. up 8%, and Rike Chemical up 6% [1] - The benchmark price for propylene oxide on January 21 is reported at 8233.33 yuan/ton, reflecting a 6.47% increase compared to the beginning of the month [1] - Over the past week (January 12 to 18), the price of propylene oxide has surged by 7.9%, leading the chemical market [1] Group 2 - Key stock performances include: - Hongbaoli with a market cap of 6.992 billion yuan and a year-to-date increase of 25.79% [2] - Jujiao Co. with a market cap of 4.897 billion yuan and a year-to-date increase of 27.46% [2] - Rike Chemical with a market cap of 3.598 billion yuan and a year-to-date increase of 15.87% [2] - Other notable stocks include Aladdin up 5.52%, Youcai Resources up 5.41%, and Qiaoyuan Co. up 5.23%, all showing strong year-to-date performance [2]